AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net revenues rose 10.2% to $17.0B as Skyrizi ($5,505M, +24.4%) and Rinvoq ($2,525M, +24.5%) more than offset Humira's 35.9% decline; net earnings reached $3,616M.
Biggest Revenue Drivers
Skyrizi$5,505M+24.4% YoY
Continued strong market share uptake as well as market growth across all indications
Rinvoq$2,525M+24.5% YoY
Continued strong market share uptake as well as market growth across all indications
Biggest Revenue Drivers
Total revenue: $17.0B+10.2% YoY
Skyrizi$5,505M+24.4% YoY
Continued strong market share uptake as well as market growth across all indications
Rinvoq$2,525M+24.5% YoY
Continued strong market share uptake as well as market growth across all indications
Vraylar$1,071M+18.9% YoY
Continued market share uptake and market growth as well as favorable pricing
Botox Therapeutic$1,042M+12.2% YoY
Market growth as well as continued market share uptake
Humira$756M-35.9% YoY
Continued impact of direct biosimilar competition following the loss of exclusivity
Largest Expense Items
Cost of products sold$4,291M
Includes $1.7 billion of intangible asset amortization; decreased amortization lowered fixed costs
Selling, general and administrative$3,632M+12% YoY
Continued leverage from net revenues growth, offset by higher litigation reserve charges
Research and development$2,344M+10% YoY
Increased to support all stages of the company's pipeline assets
Acquired IPR&D and milestones$291M
Down from $823M; prior-year quarter included $350M Gubra and $335M ADARx upfront charges
Margins: Gross margin was 75% of net revenues versus 72% a year ago, increasing primarily due to higher net revenues against lower fixed costs driven by decreased amortization of intangible assets.
Watch Items from the Filing
Three U.S. wholesalers accounted for 82% of total net accounts receivable at June 30, 2026, and substantially all U.S. pharmaceutical product net revenues.
Contingent consideration liabilities reached $27,495M, with a $1.5 billion fair value charge in the quarter driving other expense, net of $1,475M.
Humira fell to $756M from $1,180M on biosimilar competition; U.S. Humira dropped 47.0% to $425M.
Proposed $10.9 billion Apogee acquisition, backed by a new $10.0 billion 364-day term loan facility, against total deficit of $(5,888)M.
Litigation accrual was $1.7 billion; approximately 1,300 Biocell ALCL suits sit in MDL 2921, and Botox was selected for Medicare government-set prices beginning 2028.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Meyer Melody BReporting ownerGrant or award · May 8, 2026
Roberts Rebecca BReporting ownerGrant or award · May 8, 2026
Congress trading in ABBV
96 transactions in ABBV reported by 29 members of Congress under the STOCK Act, most recent trade May 5, 2026. Reported transactions, not recommendations.
About AbbVie Inc. (ABBV): stock profile, AI score and financials
AbbVie Inc. (ABBV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABBV at 72.6/100 on a composite quality score built from its SEC filings, placing it at rank #141 of 2,925 stocks — the top 5% of the AI-ranked universe. ABBV scores in the top quartile across revenue scale (97.5), earnings quality (90.8), free cash flow (82.3). Shareholder dilution risk is elevated at 44.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbbVie Inc. reports quarterly revenue of $17.0B, net income of $3.6B, an operating margin of 37.9%. Top institutional holders of ABBV by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABBV trades on the NYSE exchange and files with the SEC under CIK 1551152. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABBV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbbVie Inc. directly from SEC EDGAR.